TR200002790T2 - Composition containing 5- (4- (2- (N-methyl-N-2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione - Google Patents

Composition containing 5- (4- (2- (N-methyl-N-2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione

Info

Publication number
TR200002790T2
TR200002790T2 TR2000/02790T TR200002790T TR200002790T2 TR 200002790 T2 TR200002790 T2 TR 200002790T2 TR 2000/02790 T TR2000/02790 T TR 2000/02790T TR 200002790 T TR200002790 T TR 200002790T TR 200002790 T2 TR200002790 T2 TR 200002790T2
Authority
TR
Turkey
Prior art keywords
thiazolidin
dione
pyridyl
ethoxy
benzyl
Prior art date
Application number
TR2000/02790T
Other languages
Turkish (tr)
Inventor
Patel Jai
Ross Hamish
Price Robin
Roger Granett Jeffrey
Nigel Wray Paul
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.
Publication of TR200002790T2 publication Critical patent/TR200002790T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Terkibin farmasötik olarak kabul edilebilir formda ve farmasötik olarak kabul edilebilir bir tasiyici içinde 2 ila12 mg Bilesik (I) içermesi ile karakterize edilen bir terkip;böyle bir terkibin ilaç yapiminda kullanilmasi;böyle bir terkibin ve böyle bir proseste faydali bir ara terkibin hazirlanmasi için prosesler.A composition characterized in that the composition contains 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and in a pharmaceutically acceptable carrier; the use of such a composition in drug making; processes for preparing such a composition and a useful intermediate composition in such a process.

TR2000/02790T 1997-06-05 1998-06-02 Composition containing 5- (4- (2- (N-methyl-N-2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione TR200002790T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
TR200002790T2 true TR200002790T2 (en) 2001-11-21

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
TR1999/02963T TR199902963T2 (en) 1997-06-05 1998-06-02 Composition containing 5-$4-$2-(N-Methyl-N-2-Pyridyl)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dion
TR2000/02790T TR200002790T2 (en) 1997-06-05 1998-06-02 Composition containing 5- (4- (2- (N-methyl-N-2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR1999/02963T TR199902963T2 (en) 1997-06-05 1998-06-02 Composition containing 5-$4-$2-(N-Methyl-N-2-Pyridyl)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dion

Country Status (29)

Country Link
EP (1) EP0998284A1 (en)
JP (1) JP2001521553A (en)
KR (1) KR20010013410A (en)
CN (3) CN1112926C (en)
AP (1) AP1214A (en)
AR (2) AR008198A1 (en)
AU (1) AU8215098A (en)
BG (1) BG104048A (en)
BR (1) BR9810405A (en)
CA (2) CA2333352A1 (en)
CO (1) CO4940400A1 (en)
DZ (1) DZ2510A1 (en)
EA (1) EA002384B1 (en)
GB (1) GB9711683D0 (en)
HU (1) HUP0004070A3 (en)
ID (1) ID24264A (en)
IL (1) IL133074A0 (en)
MX (1) MXPA99011322A (en)
NO (2) NO995938L (en)
NZ (2) NZ523725A (en)
OA (1) OA11306A (en)
PE (1) PE78899A1 (en)
PL (1) PL337201A1 (en)
SK (1) SK164899A3 (en)
TR (2) TR199902963T2 (en)
TW (1) TW570797B (en)
UY (1) UY25032A1 (en)
WO (1) WO1998055122A1 (en)
ZA (2) ZA9811572B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (en) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (en) * 1987-09-04 1999-12-15 Beecham Group Plc SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
AR015120A1 (en) 2001-04-18
AR008198A1 (en) 1999-12-29
EP0998284A1 (en) 2000-05-10
CA2292629C (en) 2004-01-06
UY25032A1 (en) 1998-11-26
BG104048A (en) 2000-07-31
PL337201A1 (en) 2000-08-14
AU8215098A (en) 1998-12-21
NO20040738L (en) 2000-02-02
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
EA199901116A1 (en) 2000-06-26
CN1526391A (en) 2004-09-08
BR9810405A (en) 2000-08-29
ZA9811572B (en) 1999-07-22
OA11306A (en) 2003-10-22
HUP0004070A2 (en) 2002-02-28
CN1430959A (en) 2003-07-23
NZ523725A (en) 2004-09-24
TR199902963T2 (en) 2000-02-21
NZ513922A (en) 2001-09-28
CN1259050A (en) 2000-07-05
CA2333352A1 (en) 1998-12-10
DZ2510A1 (en) 2003-01-25
NO995938L (en) 2000-02-02
NO995938D0 (en) 1999-12-03
CN1112926C (en) 2003-07-02
WO1998055122A1 (en) 1998-12-10
KR20010013410A (en) 2001-02-26
ZA984826B (en) 1999-08-03
SK164899A3 (en) 2000-11-07
CA2292629A1 (en) 1998-12-10
MXPA99011322A (en) 2004-12-02
JP2001521553A (en) 2001-11-06
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
ID24264A (en) 2000-07-13
IL133074A0 (en) 2001-03-19
PE78899A1 (en) 1999-10-22
AP1214A (en) 2003-10-08
EA002384B1 (en) 2002-04-25
CO4940400A1 (en) 2000-07-24

Similar Documents

Publication Publication Date Title
EA200601145A1 (en) TABLET OF SLOW-DIVISION OF INSULIN SENSITIZER AND OTHER ANTI-DIABETIC AGENTS
HRP20020416B1 (en) Novel composition and use
TR200002790T2 (en) Composition containing 5- (4- (2- (N-methyl-N-2-pyridyl) amino) ethoxy) benzyl) thiazolidin-2,4-dione
NZ509239A (en) 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
TR199800697T2 (en) Pharmaceutically active quinazoline compounds.
TR200103353T2 (en) Hydrochloride salt of a fused heterocyclic composition.
TR200001793T2 (en) The thiazolidinedione derivative, the structure of which has been modified, its use in the process and pharmaceuticals for its preparation
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
TR199802626A2 (en) New pharmaceuticals.
RS49793B (en) Process for the preparation of thiazolidindione derivatives
TR200103040T2 (en) New pharmaceutical ingredients
TR200103041T2 (en) New pharmaceutical ingredients.
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
ATE337313T1 (en) 5-4'-2'-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MESYLATE SALT
CZ20011832A3 (en) Novel pharmaceutical preparation and process for preparing thereof
GB0021784D0 (en) Novel pharmaceutical
PT1446404E (en) EDISILATES OF ROSIGLITAZONE AND ITS USE AS ANTIDIABETICS
RS50130B (en) Pharmaceutical composition 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy) benzyl)thiazolidine-2,4-dione
CY1107421T1 (en) THIAZOLIDINODIONI PRODUCER TRADITIONAL SALTS
AP1738A (en) Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
ECSP003434A (en) NEW COMPOUNDS
HUP0203476A2 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same